[{"orgOrder":0,"company":"Pure MHC","sponsor":"ImmunoScape","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pure MHC","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pure MHC \/ Pure MHC","highestDevelopmentStatusID":"3","companyTruncated":"Pure MHC \/ Pure MHC"}]

Find Clinical Drug Pipeline Developments & Deals by Pure MHC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The licensing deal will allow ImmunoScape to pursue TCR-T therapeutics using this library, and accelerate identification of novel T cell receptors for therapeutic development.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 16, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : ImmunoScape

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank